MX2018001720A - Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos. - Google Patents

Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.

Info

Publication number
MX2018001720A
MX2018001720A MX2018001720A MX2018001720A MX2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A MX 2018001720 A MX2018001720 A MX 2018001720A
Authority
MX
Mexico
Prior art keywords
critical care
sedation
methods
use during
care treatment
Prior art date
Application number
MX2018001720A
Other languages
English (en)
Inventor
During Matthew
Kazanchyan Anna
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/834,027 external-priority patent/US9399034B1/en
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Priority claimed from PCT/US2016/045094 external-priority patent/WO2017027249A1/en
Publication of MX2018001720A publication Critical patent/MX2018001720A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen métodos de sedación a un paciente sometido a tratamiento de cuidado crítico utilizando gaboxadol intravenoso o una sal farmacéuticamente aceptable del mismo. Se proveen formulaciones parenterales para sedación en cuidado crítico utilizando gaboxadol o una sal farmacéuticamente aceptable del mismo. Las formulaciones parenterales son particularmente bien adecuadas para usarse en sedación para cuidado crítico.
MX2018001720A 2015-08-11 2016-08-02 Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos. MX2018001720A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562203731P 2015-08-11 2015-08-11
US201562203748P 2015-08-11 2015-08-11
US14/834,027 US9399034B1 (en) 2015-08-11 2015-08-24 Methods of sedation during critical care treatment
US15/185,650 US9717716B2 (en) 2015-08-11 2016-06-17 Methods of sedation during critical care treatment
PCT/US2016/045094 WO2017027249A1 (en) 2015-08-11 2016-08-02 Methods of sedation and parenteral formulation for use during critical care treatment

Publications (1)

Publication Number Publication Date
MX2018001720A true MX2018001720A (es) 2018-09-06

Family

ID=59687449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001720A MX2018001720A (es) 2015-08-11 2016-08-02 Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.

Country Status (12)

Country Link
US (1) US20180235942A1 (es)
EP (1) EP3334427A4 (es)
JP (1) JP6857647B2 (es)
KR (1) KR20180048707A (es)
CN (1) CN108135889A (es)
AU (1) AU2016304737B2 (es)
CA (1) CA2994952A1 (es)
CO (1) CO2018002534A2 (es)
IL (1) IL257296B2 (es)
MX (1) MX2018001720A (es)
PE (1) PE20181332A1 (es)
TW (1) TWI763632B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000745A (es) 2015-07-17 2018-08-15 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
CA3032686A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Use of ganaxolone for treating status epilepticus in a subject
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071933A (en) * 1999-12-03 2000-06-06 Diversified Medical Innovations, Inc. Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
EP1742624B1 (en) * 2004-02-18 2010-01-06 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US9399034B1 (en) * 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
IL257296B (en) 2022-10-01
CO2018002534A2 (es) 2018-05-31
AU2016304737A1 (en) 2018-02-22
JP2018522920A (ja) 2018-08-16
EP3334427A1 (en) 2018-06-20
TW201717944A (zh) 2017-06-01
PE20181332A1 (es) 2018-08-20
JP6857647B2 (ja) 2021-04-14
CN108135889A (zh) 2018-06-08
KR20180048707A (ko) 2018-05-10
IL257296B2 (en) 2023-02-01
AU2016304737B2 (en) 2021-03-11
EP3334427A4 (en) 2019-02-06
IL257296A (en) 2018-03-29
CA2994952A1 (en) 2017-02-16
US20180235942A1 (en) 2018-08-23
TWI763632B (zh) 2022-05-11

Similar Documents

Publication Publication Date Title
MX2018001720A (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
HK1252821A1 (zh) 用於治療具有rtk突變細胞的患者的組合物和方法
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
IL252689B (en) Preparations for oral administration containing octreotide in combination with other medicinal substances for the treatment of acromegaly
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
TW201713323A (en) Therapeutic compositions and methods of use thereof
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
IL273470A (en) Semaglutide in medical treatment
HK1243327A1 (zh) 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑，用於預防和/或治療過度活化的組織病症
HK1258235A1 (zh) 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL248428B (en) 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
UA81701U (ru) Способ лечения больных с частичной или полной потерей зубов со сложными анатомо-топографическими условиями челюстей
IN2014DE00822A (es)